Sorafenib
| CAS No. | 284461-73-0 | Cat. No. | BCP01767 |
| Name | Sorafenib | ||
| Synonyms | BAY 439006; BAY439006; BAY-439006;BAY 43-9006; | ||
| Formula | C21H16ClF3N4O3 | M. Wt | 464.83 |
| Description | Sorafenib is a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for use in the treatment of advanced renal cancer. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase MAPK Pathway | ||
| Targets | PDGFR VEGFR c Kit FLT3 Raf | ||
|
pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery
Publications Citing of Biochempartner's Sorafenib(CAS:284461-73-0) |
|
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways
Publications Citing of Biochempartner's Sorafenib(CAS:284461-73-0) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.